CA1065866A - Benzimidazole derivatives - Google Patents
Benzimidazole derivativesInfo
- Publication number
- CA1065866A CA1065866A CA232,438A CA232438A CA1065866A CA 1065866 A CA1065866 A CA 1065866A CA 232438 A CA232438 A CA 232438A CA 1065866 A CA1065866 A CA 1065866A
- Authority
- CA
- Canada
- Prior art keywords
- group
- benzimidazole
- ortho
- general formula
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title abstract 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 7
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims abstract description 5
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims abstract description 4
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims abstract description 4
- 125000005843 halogen group Chemical group 0.000 claims abstract description 3
- 150000001556 benzimidazoles Chemical class 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- -1 2-chloro-methyl-1-(2-hydroxybenzyl)-benzimidazole Chemical compound 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 5
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 claims description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 4
- PVKCYQIQSGNJAJ-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-4-methyl-2-(4-propylpiperazin-1-yl)benzimidazole Chemical compound C1CN(CCC)CCN1C1=NC2=C(C)C=CC=C2N1CC1=CC=C(F)C=C1 PVKCYQIQSGNJAJ-UHFFFAOYSA-N 0.000 claims description 2
- QLEIDMAURCRVCX-UHFFFAOYSA-N 1-propylpiperazine Chemical compound CCCN1CCNCC1 QLEIDMAURCRVCX-UHFFFAOYSA-N 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- JWJOLXRLRVAGCW-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-2-(4-ethylpiperazin-1-yl)-4-methylbenzimidazole Chemical compound C1CN(CC)CCN1C1=NC2=C(C)C=CC=C2N1CC1=CC=C(Cl)C=C1 JWJOLXRLRVAGCW-UHFFFAOYSA-N 0.000 claims 2
- ANBWYOCAUUGZBX-UHFFFAOYSA-N 2-(chloromethyl)-1-[(4-chlorophenyl)methyl]benzimidazole Chemical compound ClCC1=NC2=CC=CC=C2N1CC1=CC=C(Cl)C=C1 ANBWYOCAUUGZBX-UHFFFAOYSA-N 0.000 claims 1
- DODQJRXZFBJMMN-UHFFFAOYSA-N 2-[[2-(4-ethylpiperazin-1-yl)-4-methylbenzimidazol-1-yl]methyl]phenol Chemical compound C1CN(CC)CCN1C1=NC2=C(C)C=CC=C2N1CC1=CC=CC=C1O DODQJRXZFBJMMN-UHFFFAOYSA-N 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010047139 Vasoconstriction Diseases 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000025033 vasoconstriction Effects 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 2
- 229960003973 fluocortolone Drugs 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- GUHFLRTWNHWJBS-VLTGGNAYSA-N (8r,9s,10s,13s)-17-acetyl-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1C1=CC=C(C(=O)C)[C@@]1(C)CC2 GUHFLRTWNHWJBS-VLTGGNAYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SPMLMLQATWNZEE-UHFFFAOYSA-N 2-(chloromethyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(CCl)=NC2=C1 SPMLMLQATWNZEE-UHFFFAOYSA-N 0.000 description 1
- JGFCLFOKNDCXSK-UHFFFAOYSA-N 2-(pyrrolidin-1-ylmethyl)-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CN1CCCC1 JGFCLFOKNDCXSK-UHFFFAOYSA-N 0.000 description 1
- UMTRMDDIRQFQQJ-UHFFFAOYSA-N 2-[[2-(chloromethyl)benzimidazol-1-yl]methyl]phenol Chemical compound OC1=CC=CC=C1CN1C2=CC=CC=C2N=C1CCl UMTRMDDIRQFQQJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010064000 Lichenoid keratosis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 125000004803 chlorobenzyl group Chemical group 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- OSDZHDOKXGSWOD-UHFFFAOYSA-N nitroxyl;hydrochloride Chemical compound Cl.O=N OSDZHDOKXGSWOD-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2436883A DE2436883C2 (de) | 1974-07-29 | 1974-07-29 | Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1065866A true CA1065866A (en) | 1979-11-06 |
Family
ID=5922047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA232,438A Expired CA1065866A (en) | 1974-07-29 | 1975-07-29 | Benzimidazole derivatives |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US4011322A (en:Method) |
| JP (1) | JPS5136468A (en:Method) |
| AR (1) | AR207869A1 (en:Method) |
| AT (1) | AT346336B (en:Method) |
| AU (1) | AU8347175A (en:Method) |
| BE (1) | BE831856A (en:Method) |
| BG (1) | BG26374A3 (en:Method) |
| CA (1) | CA1065866A (en:Method) |
| CH (1) | CH615924A5 (en:Method) |
| CS (1) | CS189713B2 (en:Method) |
| DD (1) | DD122536A5 (en:Method) |
| DE (1) | DE2436883C2 (en:Method) |
| DK (1) | DK140634B (en:Method) |
| ES (1) | ES439811A1 (en:Method) |
| FI (1) | FI752152A7 (en:Method) |
| FR (1) | FR2280380A1 (en:Method) |
| GB (1) | GB1520262A (en:Method) |
| HU (1) | HU170517B (en:Method) |
| IE (1) | IE41503B1 (en:Method) |
| IL (1) | IL47769A (en:Method) |
| NL (1) | NL7509061A (en:Method) |
| NO (1) | NO752650L (en:Method) |
| SE (1) | SE7508544L (en:Method) |
| SU (1) | SU626698A3 (en:Method) |
| ZA (1) | ZA754884B (en:Method) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4093726A (en) * | 1976-12-02 | 1978-06-06 | Abbott Laboratories | N-(2-benzimidazolyl)-piperazines |
| JPS59199679A (ja) * | 1983-04-27 | 1984-11-12 | Kanebo Ltd | 新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物 |
| DK0632717T3 (da) * | 1992-03-23 | 1999-02-22 | Janssen Pharmaceutica Nv | Middel til anvendelse som et anti-irritationsmiddel |
| DE102006007773B4 (de) | 2006-02-20 | 2010-02-11 | Walter Dr. Kothe | Anordnung zum Spalten von Wasser |
| US8940730B2 (en) | 2007-09-18 | 2015-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
| TW200927102A (en) * | 2007-09-18 | 2009-07-01 | Univ Stanford | Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection |
| US9149463B2 (en) * | 2007-09-18 | 2015-10-06 | The Board Of Trustees Of The Leland Standford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
| US9101628B2 (en) * | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
| US8729108B2 (en) * | 2008-06-17 | 2014-05-20 | Christopher J Dannaker | Waterborne topical compositions for the delivery of active ingredients such as azelaic acid |
| WO2010107739A2 (en) * | 2009-03-18 | 2010-09-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a flaviviridae family viral infection |
| CN103298472A (zh) | 2010-03-26 | 2013-09-11 | 盖尔德马研究及发展公司 | 安全和有效治疗红斑的改进的方法和组合物 |
| AU2012324543B2 (en) | 2011-10-19 | 2017-08-10 | Galderma S.A. | Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors |
| RS61038B1 (sr) | 2013-08-19 | 2020-12-31 | Univ California | Jedinjenja i metodi za lečenje epileptičnog poremećaja |
| EP3261640B1 (en) | 2015-02-25 | 2022-04-06 | The Regents of The University of California | 5ht agonists for treating epilepsy disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620449C3 (de) * | 1964-07-23 | 1974-02-21 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Substituierte Benzimidazole und Verfahren zu ihrer Herstellung |
| GB1209558A (en) * | 1968-07-06 | 1970-10-21 | Delalande Sa | Derivatives of 5-cinnamoyl benzofuran and process for their preparation |
-
1974
- 1974-07-29 DE DE2436883A patent/DE2436883C2/de not_active Expired
-
1975
- 1975-01-01 AR AR259784A patent/AR207869A1/es active
- 1975-07-17 CS CS755082A patent/CS189713B2/cs unknown
- 1975-07-23 IL IL47769A patent/IL47769A/xx unknown
- 1975-07-23 IE IE1648/75A patent/IE41503B1/en unknown
- 1975-07-24 SU SU752159081A patent/SU626698A3/ru active
- 1975-07-25 DD DD187479A patent/DD122536A5/xx unknown
- 1975-07-28 BG BG030663A patent/BG26374A3/xx unknown
- 1975-07-28 HU HUSC527A patent/HU170517B/hu unknown
- 1975-07-28 FI FI752152A patent/FI752152A7/fi not_active Application Discontinuation
- 1975-07-28 SE SE7508544A patent/SE7508544L/xx unknown
- 1975-07-28 US US05/599,398 patent/US4011322A/en not_active Expired - Lifetime
- 1975-07-28 AT AT583775A patent/AT346336B/de not_active IP Right Cessation
- 1975-07-28 NO NO752650A patent/NO752650L/no unknown
- 1975-07-29 BE BE158719A patent/BE831856A/xx unknown
- 1975-07-29 ZA ZA00754884A patent/ZA754884B/xx unknown
- 1975-07-29 ES ES439811A patent/ES439811A1/es not_active Expired
- 1975-07-29 CH CH989775A patent/CH615924A5/de not_active IP Right Cessation
- 1975-07-29 AU AU83471/75A patent/AU8347175A/en not_active Expired
- 1975-07-29 GB GB31671/75A patent/GB1520262A/en not_active Expired
- 1975-07-29 DK DK344575AA patent/DK140634B/da not_active Application Discontinuation
- 1975-07-29 FR FR7523605A patent/FR2280380A1/fr active Granted
- 1975-07-29 NL NL7509061A patent/NL7509061A/xx not_active Application Discontinuation
- 1975-07-29 CA CA232,438A patent/CA1065866A/en not_active Expired
- 1975-07-29 JP JP50092463A patent/JPS5136468A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NO752650L (en:Method) | 1976-01-30 |
| DE2436883A1 (de) | 1976-02-19 |
| AU8347175A (en) | 1977-02-03 |
| JPS5136468A (en:Method) | 1976-03-27 |
| BG26374A3 (bg) | 1979-03-15 |
| DK140634B (da) | 1979-10-15 |
| DE2436883C2 (de) | 1985-08-22 |
| FR2280380A1 (fr) | 1976-02-27 |
| CS189713B2 (en) | 1979-04-30 |
| DK344575A (en:Method) | 1976-01-30 |
| ES439811A1 (es) | 1977-04-16 |
| IE41503B1 (en) | 1980-01-16 |
| SU626698A3 (ru) | 1978-09-30 |
| CH615924A5 (en:Method) | 1980-02-29 |
| IL47769A (en) | 1978-10-31 |
| IL47769A0 (en) | 1975-10-15 |
| ATA583775A (de) | 1978-03-15 |
| DK140634C (en:Method) | 1980-03-10 |
| SE7508544L (sv) | 1976-01-30 |
| DD122536A5 (en:Method) | 1976-10-12 |
| US4011322A (en) | 1977-03-08 |
| NL7509061A (nl) | 1976-02-02 |
| FI752152A7 (en:Method) | 1976-01-30 |
| IE41503L (en) | 1976-01-29 |
| HU170517B (en:Method) | 1977-06-28 |
| ZA754884B (en) | 1976-06-30 |
| AT346336B (de) | 1978-11-10 |
| AR207869A1 (es) | 1976-11-08 |
| GB1520262A (en) | 1978-08-02 |
| FR2280380B1 (en:Method) | 1980-04-30 |
| BE831856A (fr) | 1976-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1065866A (en) | Benzimidazole derivatives | |
| US4377584A (en) | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors | |
| USRE27253E (en) | Guiseppe palazzo | |
| EP0350846A2 (de) | Neue kondensierte heterocyclische Verbindungen und ihre Verwendung für Heilmittel | |
| JPS62234078A (ja) | ベンゾピラニルおよびベンゾチオピラニルベンゼン化合物、その製法並びに化粧品とひと・動物薬 | |
| EP0045081A2 (de) | Neue trisubstituierte Imidazolderivate, Verfahren zu ihrer Herstellung, diese enthaltende pharmazeutische Präparate und ihre Verwendung | |
| EP0084667B1 (de) | Phenylethylen-Derivate, ihre Herstellung und Verwendung als Arzneimittel | |
| FR2705095A1 (fr) | Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
| US3979361A (en) | 2-Aminomethyl-6-trihalo-methylphenols | |
| US3886278A (en) | Ammonium carboxylate sebum inhibition process | |
| US3470298A (en) | Topical anti-inflammatory composition containing (indazole-3-yl)-oxyalkanoic acids | |
| US4044153A (en) | Antiinflammatory 2-aminomethyl-6-trihalomethylphenols | |
| DE3103372A1 (de) | Neue indanyl-derivate, ihre herstellung und verwendung | |
| EP0122488B1 (de) | Bis-(Piperazinyl- bzw. Homopiperazinyl)-Alkane | |
| US3317382A (en) | Substituted 5-phenylsalicylic acid compounds for the prevention and treatment of erythema | |
| EP0072960B1 (de) | 1,5-Diphenylpyrazolin-3-on-Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| EP0033095B1 (de) | 5-Amino-tetrazol-Derivate von Retinsäuren, ihre Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
| US3968219A (en) | Hydroxy phenylbutazone derivatives and their preparation | |
| US4788209A (en) | Antifungal 2-anilinothiazolines | |
| DE2431292A1 (de) | Neue carbazol-derivate | |
| US5789409A (en) | Benzylpiperazine derivative | |
| DE69114644T2 (de) | 4(5)-Imidazole fähig zur Inhibierung von Aromatase. | |
| EP0720608B1 (de) | Neue bishispidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| US2606914A (en) | delta8(9)14-androstadienes and method of preparing the same | |
| US4595689A (en) | 4-(8-bromodibenz[b,f]oxepin-10-yl)-1,2,3,6-tetrahydro-1-methylpyridine and 4-(2-bromodibenzo[a,d]cyclophetatriene-11-yl)-1,2,3,6-tetrahydro-1-methylpyridine for dermal inflammation |